Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 355

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 355
---
   |         – |     | Level 3 |     | Black- Scholes Model |     | Volatility rate of 100% determined using historical volatility of comparable companies.                       |     | The higher the volatility the higher the fair value.     |
|                                                                   |     |   |         |     |   |           |     |         |     |                      |     | Expected life between a range of 0.1 and 1.38 years determined using the remaining life of the share options. |     | The shorter the expected life the lower the fair value.  |
|                                                                   |     |   |         |     |   |           |     |         |     |                      |     | Risk-free rate of 4.90% determined using the expected life assumptions.                                       |     | The higher the risk-free rate the higher the fair value. |

| F-15 |

| Equity settled financial derivative liability – October 2019 Warrants |     |   |         – |     |   |         – |     | Level 3 |     | 2023 – Black- Scholes Model |     | Volatility rate of 100% determined using historical volatility of comparable companies.                       |     | The higher the volatility the higher the fair value.     |
|                                                                       |     |   |           |     |   |           |     |         |     |                             |     | Expected life between a range of 0.1 and 1.00 years determined using the remaining life of the share options. |     | The shorter the expected life the lower the fair value.  |
|                                                                       |     |   |           |     |   |           |     |         |     |                             |     | Risk-free rate of 5.09% determined using the expected life assumptions.                                       |     | The higher the risk-free rate the higher the fair value. |
| Total                                                                 |     | £ | 1,159,000 |     | £ | 4,160,000 |     |         |     |                             |     |                                                                                                               |     |                                                          |

Changing the unobservable
risk-free rate input to the valuation model by 10% higher while all other variables were held constant, would not impact the carrying
amount of shares (2023: nil).

There were no transfers
between Level 1 and 2 in the period.

The financial liability
measured at fair value on Level 3 fair value measurement represents consideration relating to warrants issued in May 202